Effect of pulsed estrogen therapy on hemostatic markers in comparison with oral estrogen regimen in postmenopausal women

Gynecologic and Obstetric Investigation

Volumn 61, Issue 2, 2006, Pages 61-64

  Basurto, Lourdes ^b   Saucedo, Renata ^b   Zárate, Arturo ^a   Martínez, Carlos ^b   Gaminio, Elizabeth ^b   Reyes, Elba ^b   Hernandez, Marcelino ^b  

^a Agrarismo 208 601   (Mexico)

^b NONE

Author keywords

Coagulation; Fibrinolysis; Hormone replacement therapy; Menopause; Pulsed intranasal estradiol; Thrombotic risk factors

Indexed keywords

ANTIGEN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 7; ESTRADIOL; ESTROGEN; FIBRINOGEN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; THROMBOPLASTIN; TISSUE TYPE PLASMINOGEN ACTIVATOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FIBRINOLYSIS; HUMANS; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POSTMENOPAUSE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33344455798     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088603     Document Type: Article

References (22)

1. Colditz GA, Willet WC, Stamper MJ, Rosner B, Speizer FE, Hennekens CH: Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-1110.
2. Goldstein F, Stampfer MJ, Colditz GA: Post-menopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-1775.
3. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
4. The Women's Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004;291:1701-1712.
5. Garbe E, Suissa S: Hormone replacement therapy and acute coronary outcomes: methodological issues between randomized and observational studies. Hum Reprod 2004;19:8-13.
6. Van der Schow YT, Grobbee DE: Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of postmenopausal hormone therapy. Eur Heart J 2005;26:1358-1361.
7. Grodstein F, Clarkson TB, Manson JE: Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348:645-650.
8. Minkin MJ: Considerations in the choice of oral vs. transdermal hormone therapy: a review. J Reprod Med 2004;49:311-320.
9. Scarabin PY, Oger E: Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-432.
10. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, et al: Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619-625.
11. Martínez C, Basurto L, Zárate A, Saucedo R, Gaminio E, Collazo J: Transdermal estradiol does not impair hemostatic biomarkers in postmenopausal women. Maturitas 2005;50:39-43.
12. Kroon UB, Silfverstolpe G, Tengborn L: The effects of transdermal estradiol and oral conjugated estrogens on haemostatic variables. Thromb Haemost 1994;71:420-423.
13. Devissaguet JP, Brion N, Lhote O, Deloffre P: Pulsed estrogen therapy: pharmacokinetics of intranasal 17-beta-estradiol (S21400) in post-menopausal women and comparison with oral and transdermal formulations. Eur J Drug Metab Phamacokinet 1999;24:265-271.
14. Clauss A: Gerinnungsphysiologische Schnell-methode zur Bestimmmung des Fibronogens. Acta Haematol 1957;17:234-236.
15. Naftolin F, Taylor HS, Karas R: Early initiation of hormone therapy and clinical cardioprotection: the Women's Health Initiative (WHI) could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 2004;81:1498-1501.
16. Speroff L, Kenemans P, Burger HG: Practical guidelines for postmenopausal hormone therapy. Maturitas 2005;51:4-7.
17. Caine YG, Bauer KA, Barzegar S, ten Cate H, Sacks FM, Walsh BW: Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992;68:392-395.
18. Pinto S, Bruni V, Rosati D, Prisco D, Constanzo M, Giusti B: Effects of estrogen replacement therapy on thrombin generation. Thromb Res 1997;85:185-193.
19. Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V: Effects of hormone replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997;336:683-690.
20. Gebara OC, Mittleman MA, Walsh BW, Lipinska I, Welty FK, Belloti G: Fibrinolytic potential is significantly increased by oestrogen treatment in postmenopausal women with mild dyslipidaemia. Heart 1998;80:235-239.
21. Lowe GDO, Upton MN, Rumley A, McConnachie A, O'Reilly DJO, Watt GCM: Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C- reactive protein. A cross-sectional population survey. Thromb Haemost 2001;86:550-556.
22. Salobir BG, Keber I, Vrabic L: A randomized, placebo-controlled trial of the effects of continuous combined hormone replacement therapy on coagulation and fibrinolytic systems in healthy postmenopausal women. Fertil Steril 2002;78: 1178-1183.